search
Back to results

Effect of Oryza Sativa l Extract to LPS, ZO-1, and Intestinal Microbiota in Obese Individuals

Primary Purpose

Obesity

Status
Unknown status
Phase
Not Applicable
Locations
Indonesia
Study Type
Interventional
Intervention
Oryza Sativa Extract
Control
Sponsored by
Hasanuddin University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Lipopolysaccharide, Zonula Occludens 1, Obesity, Oryza sativa, Anthocyanin, Intestinal Microbiota

Eligibility Criteria

18 Years - 21 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria

  1. No consumption of the antioxidant supplement
  2. No consumption of prebiotic and probiotic
  3. Currently not undergo specific diet

Exclusion Criteria

  1. Current smoker
  2. Diagnosed with chronic diseases
  3. Patients with altered kidney and liver function
  4. Unable to participate for any reason

Sites / Locations

  • Hasanuddin University Medical Research Center / HUMRC

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

Obese with Oryza sativa extract

Obese with control

Normal Body Mass Index

Arm Description

The group with a body mass index of more than 25 kg/m2 that receive the Oryza Sativa Extract

The group with a body mass index of more than 25 kg/m2 that receive the citric acid and sorbitol mixture

The group with a body mass index of less than 25 kg/m2 that receive the citric acid and sorbitol mixture

Outcomes

Primary Outcome Measures

Lipopolysaccharide (LPS) level of Serum
Measured using Enzyme-Linked Immunosorbent Assay (ELISA)
Microbiota Level in Stool sample
Measured using primary PCR of total microbiota, Firmicutes-Lactobacillus, Bacteroidetes-Bacteroides fragilis, Actinobacteria-Bifidobacterium and Proteobacteria-E.Coli

Secondary Outcome Measures

Zonula Occludens 1 (ZO1) serum level
Measured using Enzyme-Linked Immunosorbent Assay (ELISA)

Full Information

First Posted
March 30, 2021
Last Updated
April 1, 2021
Sponsor
Hasanuddin University
search

1. Study Identification

Unique Protocol Identification Number
NCT04827628
Brief Title
Effect of Oryza Sativa l Extract to LPS, ZO-1, and Intestinal Microbiota in Obese Individuals
Official Title
Effect of Oryza Sativa l Extract to Serum Lipopolysaccharide, Tight Junction Protein 1 (ZO-1), and Intestinal Microbiota Expression Among Obese Individual
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Unknown status
Study Start Date
April 10, 2021 (Anticipated)
Primary Completion Date
May 1, 2021 (Anticipated)
Study Completion Date
June 1, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hasanuddin University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Background : Obesity prevalence rises among adults and leads to morbidity and mortality due to subsequent inflammation pathway activation. This activation is induced by higher lipid consumption which activates the Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) pathway and alters the microbiota profile. The Oryza sativa extract contains anthocyanin which possibly affects the microbiota composition and NF-kb pathway which eventually preserves the protective layer and tight junction of the epithelial cells. Therefore it is important to address the impact of this extract on these parameters. Objective : To assess the effect of Oryza sativa extract on microbiota profile (Lactobacillus, Firmicutes, Bacteroides, Bifidobacteria, and Escherichia coli), Lipopolysaccharide/ LPS, and the tight epithelial junction (Zonula Occludens-1) among obese adults. Method: A two-arm Quasi-Experimental will be conducted, followed by two repeated measurements, at the baseline and 3 weeks after intervention Hypothesis: Oryza sativa extract lowers the LPS level, Firmicutes sp, Bacteroides sp, and increases ZO1 protein, Bifidobacteria, and Lactobacillus sp.
Detailed Description
Method: Non Randomized clinical trial with double-blind Participants will be recruited consecutively Matching technique will be applied following several variables adjustment Two-arm of the group participants are the normal group, the obese control group, and the obese intervention group Sample size calculation: The difference between two independent means sample size calculation is applied following the elements below: a. Type 1 error: 10% b. Power: 80% c. Effect Size: 0.9 (based on changes of LPS value) d. Dropout rate: 20% e. Hypothesis: Superiority Trial g. The number of participants per group: 14 Intervention : Extract: Liquid extract of Oryza sativa derived from 10 grams of Oryza sativa fine powder. The powder is mixed with 100 ml ethanol 50% and 0.5 ml of hydrochloric acid (HCl) in 300 C for 2 hours. A supernatant is extracted and evaporated at 35 C and dried and 60 C to remove any dissolving agents. This yields an extract of 624.27 mg. Anthocyanin level is measured using a spectrophotometer where 20 microliters of extract added to 2 mL Potassium Chloride (KCl) (with pH 1.0) and 2 ml Sodium Acetate (NaCH3COO) (pH 4.5). Absorption of 500 nm and 700 nm waves are measured and calculated using the cyanide-3-glucoside calculation where : anthocyanin level : (absorbance x 449.2 x dilution factor x 1000) / 26.9 Control a. Active comparator using citric acid and sorbitol mixture Biological sample: Serum sample preparation : Participants should undergo fasting for 12 hours. Blood is drawn from the cubital vein to the plain tube and incubated for 30-45 minutes. Centrifugation of sample is done for 15 minutes with 3000 rotation per minute to yield the serum. The supernatant then extracted and stored at -80 C. Feces primary Polymerase Chain Reaction (PCR) using 100-gram feces. The PCR primer for intestinal microbiota are enlisted below : Total intestinal microbiota (ACTCCTACGGGAGGCAGCAGT ATTACCGCGGCTGCTGGC), Firmicutes-Lactobacillus (TACATCCCAACTCCAGAACGAAGCAACAGTACCACGACC)), Bacteroidetes-Bacteroides fragilis (ATAGCCTTCGAAAGRAAGATCCAGTATCAACTGCAATTTTA), Actinobacteria-Bifidobacterium (CTCCTGGAAACGGGGTGGGGTGTTCTTCCCGATATCTACA), Proteobacteria-E.Coli (CATGCCGCGTGTATGAAGAACGGGTAACGTCAATGAGCAAA) Protection of Human subject according to Helsinki Declaration Participants are allowed to receive the information of research including purpose, possible intervention, and side effects. Possible side effect including : Participants are allowed to withdraw from the study for any reason. Statistical Analysis Plan Descriptive statistic of the baseline The bivariate analysis between all variables and the outcomes Paired t-test is intended to see the difference between microbiota profile, LPS, and ZO1 within groups The independent-test to measure the difference in microbiota profile, LPS, and ZO1 value between groups Alternative statistical test: Linear mixed model to adjust the fixed and random effects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Lipopolysaccharide, Zonula Occludens 1, Obesity, Oryza sativa, Anthocyanin, Intestinal Microbiota

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
a non-randomized trial is implemented involving three arms consists of an obese group as the intervention and two control groups, people with normal Body Mass Index, and Obese.
Masking
ParticipantCare ProviderOutcomes Assessor
Masking Description
To blind the participant, the mixture is given in the darker bottle, and placebo is given the artificial taste similar to the intervention group. This adjustment also blinds the care provider. The outcome assessor is blinded from the allocation of the group.
Allocation
Non-Randomized
Enrollment
42 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Obese with Oryza sativa extract
Arm Type
Experimental
Arm Description
The group with a body mass index of more than 25 kg/m2 that receive the Oryza Sativa Extract
Arm Title
Obese with control
Arm Type
Active Comparator
Arm Description
The group with a body mass index of more than 25 kg/m2 that receive the citric acid and sorbitol mixture
Arm Title
Normal Body Mass Index
Arm Type
Active Comparator
Arm Description
The group with a body mass index of less than 25 kg/m2 that receive the citric acid and sorbitol mixture
Intervention Type
Dietary Supplement
Intervention Name(s)
Oryza Sativa Extract
Intervention Description
The product is a suspension of 5.6 gram/100 mL given once daily, contains 71.9%, purple in color, range pH 3-5. Stored in the darker bottle. The frequency of administration is once-daily after the meal.
Intervention Type
Dietary Supplement
Intervention Name(s)
Control
Intervention Description
citric acid 0.1g/oz and 1% sorbitol mixture, given once daily after meal
Primary Outcome Measure Information:
Title
Lipopolysaccharide (LPS) level of Serum
Description
Measured using Enzyme-Linked Immunosorbent Assay (ELISA)
Time Frame
Changes of LPS value from baseline to the last day of intervention (three weeks)
Title
Microbiota Level in Stool sample
Description
Measured using primary PCR of total microbiota, Firmicutes-Lactobacillus, Bacteroidetes-Bacteroides fragilis, Actinobacteria-Bifidobacterium and Proteobacteria-E.Coli
Time Frame
Changes of Microbiota value from baseline to the last day of intervention (three weeks)
Secondary Outcome Measure Information:
Title
Zonula Occludens 1 (ZO1) serum level
Description
Measured using Enzyme-Linked Immunosorbent Assay (ELISA)
Time Frame
Changes of ZO1 value from baseline to the last day of intervention (three weeks)

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria No consumption of the antioxidant supplement No consumption of prebiotic and probiotic Currently not undergo specific diet Exclusion Criteria Current smoker Diagnosed with chronic diseases Patients with altered kidney and liver function Unable to participate for any reason
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bumi Herman, Ph.D
Phone
+66638275008
Email
bumiherman@med.unhas.ac.id
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Agussalim Bukhari, Ph.D
Organizational Affiliation
Hasanuddin University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Nurpudji Taslim, Prof.
Organizational Affiliation
Hasanuddin University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Aminuddin Aminuddin, Ph.D
Organizational Affiliation
Hasanuddin University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Armanto Makmun, M.Kes
Organizational Affiliation
Universitas Muslim Indonesia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rachmat Syamsu, M.Kes
Organizational Affiliation
Universitas Muslim Indonesia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bumi Herman, MD. Ph.D
Organizational Affiliation
Chulalongkorn University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hasanuddin University Medical Research Center / HUMRC
City
Makassar
State/Province
South Sulawesi
ZIP/Postal Code
90245
Country
Indonesia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Armanto Makmun, M.Kes
Phone
+6285299900032
Email
armanto.makmun@umi.ac.id
First Name & Middle Initial & Last Name & Degree
Rachmat Syamsu, M.Kes
Phone
+6285242150099
Email
rachmatfaisal.syamsu@umi.ac.id
First Name & Middle Initial & Last Name & Degree
Armanto Makmun, M.Kes
First Name & Middle Initial & Last Name & Degree
Agussalim Bukhari, Ph.D
First Name & Middle Initial & Last Name & Degree
Aminuddin Aminuddin, Ph.D
First Name & Middle Initial & Last Name & Degree
Nurpudji A Taslim, Prof
First Name & Middle Initial & Last Name & Degree
Rachmat F Syamsu, M.Kes
First Name & Middle Initial & Last Name & Degree
Bumi Herman, Ph.D

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Only protocol could be shared for public
Citations:
PubMed Identifier
27682087
Citation
Aguirre M, Venema K. Does the Gut Microbiota Contribute to Obesity? Going beyond the Gut Feeling. Microorganisms. 2015 Apr 27;3(2):213-35. doi: 10.3390/microorganisms3020213.
Results Reference
background
PubMed Identifier
22191449
Citation
Angelakis E, Armougom F, Million M, Raoult D. The relationship between gut microbiota and weight gain in humans. Future Microbiol. 2012 Jan;7(1):91-109. doi: 10.2217/fmb.11.142.
Results Reference
background
PubMed Identifier
22339979
Citation
Tehrani AB, Nezami BG, Gewirtz A, Srinivasan S. Obesity and its associated disease: a role for microbiota? Neurogastroenterol Motil. 2012 Apr;24(4):305-11. doi: 10.1111/j.1365-2982.2012.01895.x. Epub 2012 Feb 20.
Results Reference
background
PubMed Identifier
31614770
Citation
Tan J, Li Y, Hou DX, Wu S. The Effects and Mechanisms of Cyanidin-3-Glucoside and Its Phenolic Metabolites in Maintaining Intestinal Integrity. Antioxidants (Basel). 2019 Oct 12;8(10):479. doi: 10.3390/antiox8100479.
Results Reference
background
PubMed Identifier
27260462
Citation
Morais CA, de Rosso VV, Estadella D, Pisani LP. Anthocyanins as inflammatory modulators and the role of the gut microbiota. J Nutr Biochem. 2016 Jul;33:1-7. doi: 10.1016/j.jnutbio.2015.11.008. Epub 2015 Nov 26.
Results Reference
background
PubMed Identifier
20669401
Citation
Min SW, Ryu SN, Kim DH. Anti-inflammatory effects of black rice, cyanidin-3-O-beta-D-glycoside, and its metabolites, cyanidin and protocatechuic acid. Int Immunopharmacol. 2010 Aug;10(8):959-66. doi: 10.1016/j.intimp.2010.05.009.
Results Reference
background
PubMed Identifier
30648119
Citation
Lee B, Moon KM, Kim CY. Tight Junction in the Intestinal Epithelium: Its Association with Diseases and Regulation by Phytochemicals. J Immunol Res. 2018 Dec 16;2018:2645465. doi: 10.1155/2018/2645465. eCollection 2018.
Results Reference
background
PubMed Identifier
31394335
Citation
Ito VC, Lacerda LG. Black rice (Oryza sativa L.): A review of its historical aspects, chemical composition, nutritional and functional properties, and applications and processing technologies. Food Chem. 2019 Dec 15;301:125304. doi: 10.1016/j.foodchem.2019.125304. Epub 2019 Jul 31.
Results Reference
background
PubMed Identifier
29984532
Citation
Igwe EO, Charlton KE, Probst YC, Kent K, Netzel ME. A systematic literature review of the effect of anthocyanins on gut microbiota populations. J Hum Nutr Diet. 2019 Feb;32(1):53-62. doi: 10.1111/jhn.12582. Epub 2018 Jul 8.
Results Reference
background
PubMed Identifier
26712364
Citation
Hersoug LG, Moller P, Loft S. Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. Obes Rev. 2016 Apr;17(4):297-312. doi: 10.1111/obr.12370. Epub 2015 Dec 29.
Results Reference
background
PubMed Identifier
30263677
Citation
Bae IY, An JS, Oh IK, Lee HG. Optimized preparation of anthocyanin-rich extract from black rice and its effects on in vitro digestibility. Food Sci Biotechnol. 2017 Aug 28;26(5):1415-1422. doi: 10.1007/s10068-017-0188-x. eCollection 2017.
Results Reference
background

Learn more about this trial

Effect of Oryza Sativa l Extract to LPS, ZO-1, and Intestinal Microbiota in Obese Individuals

We'll reach out to this number within 24 hrs